Circulating Neoplastic-Immune Hybrid Cells Predict Metastatic Progression in Uveal Melanoma
Background: Uveal melanoma is an aggressive cancer with high metastatic risk. Recently, we identified a circulating cancer cell population that co-expresses neoplastic and leukocyte antigens, termed circulating hybrid cells (CHCs). In other cancers, CHCs are more numerous and better predict oncologi...
| Main Authors: | , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-09-01
|
| Series: | Cancers |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2072-6694/14/19/4617 |
| _version_ | 1797480336840458240 |
|---|---|
| author | Michael S. Parappilly Yuki Chin Riley M. Whalen Ashley N. Anderson Trinity S. Robinson Luke Strgar Thomas L. Sutton Patrick Conley Christopher Klocke Summer L. Gibbs Young Hwan Chang Guanming Wu Melissa H. Wong Alison H. Skalet |
| author_facet | Michael S. Parappilly Yuki Chin Riley M. Whalen Ashley N. Anderson Trinity S. Robinson Luke Strgar Thomas L. Sutton Patrick Conley Christopher Klocke Summer L. Gibbs Young Hwan Chang Guanming Wu Melissa H. Wong Alison H. Skalet |
| author_sort | Michael S. Parappilly |
| collection | DOAJ |
| description | Background: Uveal melanoma is an aggressive cancer with high metastatic risk. Recently, we identified a circulating cancer cell population that co-expresses neoplastic and leukocyte antigens, termed circulating hybrid cells (CHCs). In other cancers, CHCs are more numerous and better predict oncologic outcomes compared to circulating tumor cells (CTCs). We sought to investigate the potential of CHCs as a prognostic biomarker in uveal melanoma. Methods: We isolated peripheral blood monocular cells from uveal melanoma patients at the time of primary treatment and used antibodies against leukocyte and melanoma markers to identify and enumerate CHCs and CTCs by immunocytochemistry. Results: Using a multi-marker approach to capture the heterogeneous disseminated tumor cell population, detection of CHCs was highly sensitive in uveal melanoma patients regardless of disease stage. CHCs were detected in 100% of stage I-III uveal melanoma patients (entire cohort, <i>n</i> = 68), whereas CTCs were detected in 58.8% of patients. CHCs were detected at levels statically higher than CTCs across all stages (<i>p</i> = 0.05). Moreover, CHC levels, but not CTCs, predicted 3 year progression-free survival (<i>p</i> < 0.03) and overall survival (<i>p</i> < 0.04). Conclusion: CHCs are a novel and promising prognostic biomarker in uveal melanoma. |
| first_indexed | 2024-03-09T21:59:05Z |
| format | Article |
| id | doaj.art-e4a07db2af2e40499c10891251478186 |
| institution | Directory Open Access Journal |
| issn | 2072-6694 |
| language | English |
| last_indexed | 2024-03-09T21:59:05Z |
| publishDate | 2022-09-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Cancers |
| spelling | doaj.art-e4a07db2af2e40499c108912514781862023-11-23T19:53:44ZengMDPI AGCancers2072-66942022-09-011419461710.3390/cancers14194617Circulating Neoplastic-Immune Hybrid Cells Predict Metastatic Progression in Uveal MelanomaMichael S. Parappilly0Yuki Chin1Riley M. Whalen2Ashley N. Anderson3Trinity S. Robinson4Luke Strgar5Thomas L. Sutton6Patrick Conley7Christopher Klocke8Summer L. Gibbs9Young Hwan Chang10Guanming Wu11Melissa H. Wong12Alison H. Skalet13Department of Cell, Developmental and Cancer Biology, Oregon Health & Science University, Portland, OR 97201, USADepartment of Cell, Developmental and Cancer Biology, Oregon Health & Science University, Portland, OR 97201, USADepartment of Cell, Developmental and Cancer Biology, Oregon Health & Science University, Portland, OR 97201, USADepartment of Cell, Developmental and Cancer Biology, Oregon Health & Science University, Portland, OR 97201, USADepartment of Cell, Developmental and Cancer Biology, Oregon Health & Science University, Portland, OR 97201, USADepartment of Biomedical Engineering, Oregon Health & Science University, Portland, OR 97201, USADepartment of Surgery, Oregon Health & Science University, Portland, OR 97239, USADepartment of Medical Informatics and Clinical Epidemiology, Oregon Health & Science University, Portland, OR 97239, USADepartment of Medical Informatics and Clinical Epidemiology, Oregon Health & Science University, Portland, OR 97239, USADepartment of Biomedical Engineering, Oregon Health & Science University, Portland, OR 97201, USADepartment of Biomedical Engineering, Oregon Health & Science University, Portland, OR 97201, USADepartment of Medical Informatics and Clinical Epidemiology, Oregon Health & Science University, Portland, OR 97239, USADepartment of Cell, Developmental and Cancer Biology, Oregon Health & Science University, Portland, OR 97201, USAKnight Cancer Institute, Oregon Health & Science University, Portland, OR 97201, USABackground: Uveal melanoma is an aggressive cancer with high metastatic risk. Recently, we identified a circulating cancer cell population that co-expresses neoplastic and leukocyte antigens, termed circulating hybrid cells (CHCs). In other cancers, CHCs are more numerous and better predict oncologic outcomes compared to circulating tumor cells (CTCs). We sought to investigate the potential of CHCs as a prognostic biomarker in uveal melanoma. Methods: We isolated peripheral blood monocular cells from uveal melanoma patients at the time of primary treatment and used antibodies against leukocyte and melanoma markers to identify and enumerate CHCs and CTCs by immunocytochemistry. Results: Using a multi-marker approach to capture the heterogeneous disseminated tumor cell population, detection of CHCs was highly sensitive in uveal melanoma patients regardless of disease stage. CHCs were detected in 100% of stage I-III uveal melanoma patients (entire cohort, <i>n</i> = 68), whereas CTCs were detected in 58.8% of patients. CHCs were detected at levels statically higher than CTCs across all stages (<i>p</i> = 0.05). Moreover, CHC levels, but not CTCs, predicted 3 year progression-free survival (<i>p</i> < 0.03) and overall survival (<i>p</i> < 0.04). Conclusion: CHCs are a novel and promising prognostic biomarker in uveal melanoma.https://www.mdpi.com/2072-6694/14/19/4617uveal melanomacirculating hybrid cellscancer biomarkercirculating tumor cells |
| spellingShingle | Michael S. Parappilly Yuki Chin Riley M. Whalen Ashley N. Anderson Trinity S. Robinson Luke Strgar Thomas L. Sutton Patrick Conley Christopher Klocke Summer L. Gibbs Young Hwan Chang Guanming Wu Melissa H. Wong Alison H. Skalet Circulating Neoplastic-Immune Hybrid Cells Predict Metastatic Progression in Uveal Melanoma Cancers uveal melanoma circulating hybrid cells cancer biomarker circulating tumor cells |
| title | Circulating Neoplastic-Immune Hybrid Cells Predict Metastatic Progression in Uveal Melanoma |
| title_full | Circulating Neoplastic-Immune Hybrid Cells Predict Metastatic Progression in Uveal Melanoma |
| title_fullStr | Circulating Neoplastic-Immune Hybrid Cells Predict Metastatic Progression in Uveal Melanoma |
| title_full_unstemmed | Circulating Neoplastic-Immune Hybrid Cells Predict Metastatic Progression in Uveal Melanoma |
| title_short | Circulating Neoplastic-Immune Hybrid Cells Predict Metastatic Progression in Uveal Melanoma |
| title_sort | circulating neoplastic immune hybrid cells predict metastatic progression in uveal melanoma |
| topic | uveal melanoma circulating hybrid cells cancer biomarker circulating tumor cells |
| url | https://www.mdpi.com/2072-6694/14/19/4617 |
| work_keys_str_mv | AT michaelsparappilly circulatingneoplasticimmunehybridcellspredictmetastaticprogressioninuvealmelanoma AT yukichin circulatingneoplasticimmunehybridcellspredictmetastaticprogressioninuvealmelanoma AT rileymwhalen circulatingneoplasticimmunehybridcellspredictmetastaticprogressioninuvealmelanoma AT ashleynanderson circulatingneoplasticimmunehybridcellspredictmetastaticprogressioninuvealmelanoma AT trinitysrobinson circulatingneoplasticimmunehybridcellspredictmetastaticprogressioninuvealmelanoma AT lukestrgar circulatingneoplasticimmunehybridcellspredictmetastaticprogressioninuvealmelanoma AT thomaslsutton circulatingneoplasticimmunehybridcellspredictmetastaticprogressioninuvealmelanoma AT patrickconley circulatingneoplasticimmunehybridcellspredictmetastaticprogressioninuvealmelanoma AT christopherklocke circulatingneoplasticimmunehybridcellspredictmetastaticprogressioninuvealmelanoma AT summerlgibbs circulatingneoplasticimmunehybridcellspredictmetastaticprogressioninuvealmelanoma AT younghwanchang circulatingneoplasticimmunehybridcellspredictmetastaticprogressioninuvealmelanoma AT guanmingwu circulatingneoplasticimmunehybridcellspredictmetastaticprogressioninuvealmelanoma AT melissahwong circulatingneoplasticimmunehybridcellspredictmetastaticprogressioninuvealmelanoma AT alisonhskalet circulatingneoplasticimmunehybridcellspredictmetastaticprogressioninuvealmelanoma |